Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: A prospective 24-month case series

Maurizio Battaglia Parodi, Pierluigi Iacono, Alexandros Papayannis, Stelios Dimitrios Kontadakis, Marialucia Cascavilla, Luisa Pierro, Marco Gagliardi, Francesco Bandello

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To assess the effects of intravitreal ranibizumab injection in patients affected by pigment epithelial detachment associated with occult subfoveal choroidal neovascularization. Design: Prospective, interventional case series. Methods: Participants: Forty eyes of 40 patients were considered for the purpose of the study. Consecutive patients were recruited for a 24-month study. All patients underwent a complete ophthalmic examination, including best-corrected visual acuity on Early Treatment Diabetic Retinopathy Study (ETDRS) charts. After a 3-monthly loading phase, further intravitreal ranibizumab injections were administered on the basis of detection of any type of fluid on optical coherence tomography. Primary outcome measures: Changes in mean best-corrected visual acuity at 12 and 24 months and the proportion of eyes losing fewer than 15 letters (corresponding to 3 ETDRS lines) from baseline visual acuity. Secondary outcome measures: Changes in central macular thickness on optical coherence tomography and variation in mean area of the entire lesion. Results: Forty patients were included. Mean best-corrected visual acuity decreased from 20/66 (58 ETDRS letters) to 20/83 (53 letters) at 12 months and 20/112 (489 ETDRS letters) at 24 months (P =.003). Eighty percent and 67.5% of eyes lost fewer than 3 lines at 12 and 24 months, respectively. Mean central macular thickness passed from 545 μm to 428 μm at 12 months and 426 μm at 24 months. Mean lesion area changed from 6826 μm2 to 6312 μm2 at 12 months and 6010 μm2 at 24 months. Conclusions: The treatment of pigment epithelial detachment associated with occult subfoveal choroidal neovascularization with intravitreal ranibizumab injection after a 3-monthly loading phase and pro re nata strategy can lead to partial results over a 24-month follow-up. Further investigations are warranted to establish the best therapeutic approach to this disease.

Original languageEnglish
Pages (from-to)103-108
Number of pages6
JournalAmerican Journal of Ophthalmology
Volume155
Issue number1
DOIs
Publication statusPublished - Jan 2013

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: A prospective 24-month case series'. Together they form a unique fingerprint.

Cite this